PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This is a Pharmacokinetic and Pharmacodynamic study evaluating the safety of co-administering
Azithromycin alongside the new IDA (Ivermectin, Diethylcarbamazine, Albendazole) combination
treatment for LF. Individuals will be randomised to receive Azithromycin alone, IDA or
combination therapy. Clinical and biochemical monitoring for safety will be undertaken. Drug
levels will be measured in each of the three arms to assess whether combination therapy
significantly alters drug levels.